Search clinical trials for: MVA85A

Total 25 results

University of Oxford
Imaxio

Completed

Phase I Trial Evaluating Safety and Immunogenicity of MVA85A-IMX313 Compared to MVA85A in BCG Vaccinated Adults

Tuberculosis (TB)

United Kingdom
University of Oxford

Completed

Safety of Tuberculosis Vaccine, MVA85A, Administered by the Aerosol Route and the Intradermal Route

Tuberculosis

United Kingdom
University of Oxford
University of Birmingham

Terminated

MVA85A Aerosol vs Intramuscular Vaccination in Adults With Latent Mycobacterium Tuberculosis (M. tb) Infection

Tuberculosis

United Kingdom
University of Oxford

Completed

A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG

Tuberculosis

United Kingdom
University of Oxford

Completed

Study Evaluating Aerosol and Intradermal Administration of a Candidate Tuberculosis (TB) Vaccine, MVA85A, as a Way to Increase Immune Response and Avoid Anti-vector Immunity

Tuberculosis

United Kingdom
University of Oxford
University of Birmingham

Completed

Safety Study of ChAdOx1 85A Vaccination With and Without MVA85A Boost in Healthy Adults

Tuberculosis

United Kingdom
University of Oxford

Completed

A Phase I Study to Assess the Safety and Immunogenicity of Tuberculosis (TB) Vaccine Candidates FP85A and MVA85A

Tuberculosis

United Kingdom
University of Oxford

Completed

A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Received BCG Immunisation 1 Month Previously

Tuberculosis

United Kingdom
University of Oxford

Completed

A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers.

Tuberculosis

United Kingdom
University of Oxford
Centre Hospitalier Universitaire Le Dantec, Dakar, Senegal

Completed

A Phase I Study of a New Tuberculosis (TB) Vaccine, MVA85A, in Healthy Volunteers With HIV

Tuberculosis

Senegal
University of Oxford
MRC/UVRI and LSHTM Uganda Research Unit

Completed

EMaBS TB Vaccine Study

Safety | Immunogenicity

United Kingdom, Uganda
University of Oxford

Completed

A Phase I Study of the Safety and Immunogenicity of MVA85A in Healthy Gambian Volunteers

Tuberculosis

Gambia
University of Oxford
MRC/UVRI and LSHTM Uganda Research Unit

Completed

Trial to Investigate the Effect of Schistosoma Mansoni Infection on the Response to Vaccination With MVA85A in BCG-vaccinated African Adolescents (TB036)

Tuberculosis

Uganda
University of Oxford
Wellcome Trust; St George's, University of London

Completed

T-Cell Turnover Following Vaccination With MVA85A

Tuberculosis

United Kingdom
University of Oxford
Crucell Holland BV; University of Birmingham; Emergent BioSolutions; Aeras

Completed

Safety Study of Tuberculosis Vaccines AERAS-402 and MVA85A

Tuberculosis

United Kingdom
Aeras
University of Oxford; European and Developing Countries Clinical Trials Partnership...

Completed

Efficacy Against TB Disease, Safety, and Immunogenicity of MVA85A/AERAS-485 in HIV-Infected Adults (C-030-485)

HIV Infections | Tuberculosis

South Africa, Senegal
Mark Hatherill
Medical Research Council; University of Oxford; Wellcome Trust; Department for... and other collaborators

Completed

Safety and Immunogenicity of MVA85A Prime and Bacille Calmette-Guerin Boost Vaccination (MVA(TB)029)

HIV | Tuberculosis

South Africa
University of Oxford

Completed

The Safety and Immunogenicity of a TB Vaccine; MVA85A, in Healthy Volunteers Who Are Infected With HIV

HIV Infections | Tuberculosis

United Kingdom
University of Oxford
University of Cape Town

Completed

A Study of MVA85A in Healthy Children and Infants

Tuberculosis

South Africa
Aeras
University of Oxford; University of Cape Town

Completed

A Study of MVA85A in Healthy Infants

Tuberculosis

South Africa
University of Oxford

Completed

A BCG Challenge Model Study to Assess Anti-mycobacterial Immunity Induced by BCG and a Candidate TB Vaccine, MVA85A

Tuberculosis

United Kingdom
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer

Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IV Colon Cancer | Stage IV Rectal Cancer | Stage IV Gastric Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Recurrent Gastric Cancer | Stage III Colon Cancer | Stage III Gastric Cancer | Stage III Rectal...

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy

Melanoma | Soft Tissue Sarcoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Head and Neck Squamous Cell Carcinoma | Bladder Carcinoma | Colon Carcinoma | Pancreatic Carcinoma | Rectal Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Platinum-Resistant Fallopian Tube Carcinoma | Recurrent Platinum-Resistant Primary Peritoneal Carcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Ovarian Epithelial Cancer

United States

Search clinical trials for: MVA85A

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations